"目录号: HY-14655
Sulfasalazine是治疗类风湿关节炎和溃疡性结肠炎的药物。
相关产品
Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-
生物活性
Description
Sulfasalazine is a drug for the treatment of rheumatoid arthritis and ulcerative colitis.
In Vitro
Treatment of SW620 colon cells with sulfasalazine inhibits TNFα-, LPS-, or phorbol ester-induced NFκB activation. NFκB–dependent transcription is inhibited by sulfasalazine at micro- to millimolar concentrations. TNFα-induced nuclear translocation of NFκB is prevented by sulfasalazine through inhibition of IκBα degradation[1]. Pre‐incubation with 5 mM of sulfasalazine alone significantly increases basal mRNA expression of all pro‐inflammatory cytokines with levels of IL‐6 mRNA increased by 80‐fold compared with vehicle control[2]. Once digested, sulfasalazine is cleaved into sulfapyridine and 5-aminosalicylic acid by colonic bacteria, and the latter, too, is reported to suppress NF-kappaB activity[3].
In Vivo
At low doses (0.25 mM), SAS is able to suppress glioma growth by over 60% compared to untreated controls[3].
Clinical Trial
Pfizer
Arthritis, Juvenile Rheumatoid
June 2010
Phase 4
University of Alabama at Birmingham
Brain Tumor
January 2012
The Mind Research Network
Alcohol Dependence
March 2010
Boston University
Coronary Artery Disease
July 2003
Alliance for Clinical Trials in Oncology-National Cancer Institute (NCI)
Diarrhea-Gastrointestinal Complications-Unspecified Adult Solid Tumor, Protocol Specific
April 2011
Phase 3
Singapore General Hospital
Rheumatoid Arthritis
July 2012
Phase 4
Massachusetts General Hospital
Painful Neuropathy
May 2013
Phase 2
Charite University, Berlin, Germany-Wyeth is now a wholly owned subsidiary of Pfizer
Moderate to Severe Active Axial Spondyloarthritis
November 2005
Phase 2
University Medicine Greifswald
Pharmacokinetics-Magnetic Resonance Imaging-Administration, Oral
April 2016
Phase 1
University of Nebraska
Rheumatoid Arthritis
December 1999
Phase 3
Tesaro, Inc.
Chemotherapy-induced Nausea and Vomiting
May 2015
Phase 1
Jawaharlal Institute of Postgraduate Medical Education & Research
Rheumatoid Arthritis
September 2016
Phase 4
Chung Shan Medical University
Ankylosing Spondylitis
November 2009
Phase 2
Zhixiang Huang-Health and Family Planning Commission of Guangdong
Ankylosing Spondylitis
January 2016
Phase 4
VA Office of Research and Development-Canadian Institutes of Health Research (CIHR)-Rheumatoid Arthritis Investigational Network (RAIN)-National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Rheumatoid Arthritis
July 2007
Brigham and Women's Hospital-Columbia University
Arthritis, Rheumatoid
July 2016
Phase 4
Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis
June 2007
Phase 4
University of Alabama at Birmingham-Amgen-Barr Laboratories-Pfizer
Rheumatoid Arthritis
May 2004
Phase 4
Sun Yat-sen University
Early Ankylosing Spondylitis
October 2008
Phase 2-Phase 3
Merck Sharp & Dohme Corp.-AESCA Pharma GmbH
Rheumatoid Arthritis
June 2007
Phase 3
Sanofi
Rheumatoid Arthritis
October 2012
Phase 3
Hoffmann-La Roche
Rheumatoid Arthritis
November 2013
Phase 3
Sanofi-Regeneron Pharmaceuticals
Rheumatoid Arthritis
March 2013
Phase 3
Sanofi-Regeneron Pharmaceuticals
RA
March 2014
Phase 3
Sanofi-Regeneron Pharmaceuticals
Rheumatoid Arthritis
February 2015
Phase 3
University of Leeds
Rheumatoid Arthritis
July 2011
Phase 4
University Medicine Greifswald
Intestinal Obstruction
January 2010
Phase 1
University Medicine Greifswald
Intestinal Obstruction
May 2011
Phase 1
View MoreCollapse
References
